Current mathematical models for cancer drug discovery. (3rd August 2017)

• Record Type: Journal Article
• Authors: Carrara, Letizia; Lavezzi, Silvia Maria; Borella, Elisa; De Nicolao, Giuseppe; Magni, Paolo; Poggesi, Italo
• Is Part Of: Expert opinion on drug discovery. Volume 12:Number 8(2017:Aug.)
• Page Start: 785
• Page End: 799
• Publication Date: 2017-08-03
• Subjects: Combination therapy -- drug candidates -- in vitro -- in vivo -- mathematical modeling -- oncology -- pharmacometrics -- PK-PD -- single agent -- translational pharmacology; 615.1
• DOI: 10.1080/17460441.2017.1340271
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction : Pharmacometric models represent the most comprehensive approaches for extracting, summarizing and integrating information obtained in the often sparse, limited, and less-than-optimally designed experiments performed in the early phases of oncology drug discovery. Whilst empirical methodologies may be enough for screening and ranking candidate drugs, modeling approaches are needed for optimizing and making economically viable the learn-confirm cycles within an oncology research program and anticipating the dose regimens to be investigated in the subsequent clinical development. Areas covered : Papers appearing in the literature of approximately the last decade reporting modeling approaches applicable to anticancer drug discovery have been listed and commented. Papers were selected based on the interest in the proposed methodology or in its application. Expert opinion : The number of modeling approaches used in the discovery of anticancer drugs is consistently increasing and new models are developed based on the current directions of research of new candidate drugs. These approaches have contributed to a better understanding of new oncological targets and have allowed for the exploitation of the relatively sparse information generated by preclinical experiments. In addition, they are used in translational approaches for guiding and supporting the choice of dosing regimens in early clinical development.